Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLS-005 (Trehalose) in Alzheimer's Disease
NCT05332678Phase 2Withdrawn
- Sponsor
- Seelos Therapeutics, Inc.
- Start
- Mar 2023
- Primary completion
- Apr 2023
- Modality
- Drug Delivery Systems, DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of trehalose in Alzheimer's disease (AD), sponsored by Seelos Therapeutics, Inc.. Planned start Mar 2023; status: withdrawn.
02
Drugs
trehalose
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05332678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05332678.